

HR 2113

Speeding Access to Already Approved Pharmaceuticals Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 20, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 21, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/2113>

Sponsor

Name: Rep. Stivers, Steve [R-OH-15]

Party: Republican • **State:** OH • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Ryan, Tim [D-OH-13]	D · OH		Apr 20, 2017
Rep. Bacon, Don [R-NE-2]	R · NE		May 16, 2017

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 21, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 20, 2017)

Speeding Access to Already Approved Pharmaceuticals Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to facilitate the development and expedite the review of a new drug, biological product, or medical device that has been approved in the European Union.

Actions Timeline

- **Apr 21, 2017:** Referred to the Subcommittee on Health.
- **Apr 20, 2017:** Introduced in House
- **Apr 20, 2017:** Referred to the House Committee on Energy and Commerce